Market Access

Bill McElnea and Hinal Sharma discuss how the role of a specialty pharmacy will evolve in the next few years.

Live from Asembia AXS26, Austin Russian examines how specialty therapy launches are evolving.

Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion transaction that expands its presence in the US rare disease market and adds a portfolio of neuromuscular and neurological therapies.

Jennifer Lospinoso shares how cell and gene therapy access models differ from normal specialty medications, and how the market will adapt in the next five years.

Will Shrank, MD, explains how the specialty pharma pipeline could pose access risks in the future.

In this week's Pharma Pulse, Eli Lilly opens its new genetic medicine plant, Bayer acquires Perfuse Therapeutics, and more.

As specialty drug costs rise, employers and sponsors must balance alternative funding programs and in-benefit optimization to achieve sustainable savings without disrupting patient care.

GoodRx now offers oral Ozempic as an alternative to injectable GLP-1 therapies.

As cell and gene therapies move beyond ultra-rare disease indications into broader patient populations, the commercialization infrastructure built around them is due for a fundamental redesign.

At Asembia AXS26, Dee Chaudhary broke down how shifting US drug pricing policy is tightening payer controls and changing pharmaceutical pricing and forecasting.

Avalere Health analysts map the converging pressures reshaping the drug pricing and distribution landscape ahead of November.

TailorMed broadens patient support beyond copay help, adding five modules that link access, affordability and adherence across specialty medications.

Charley Maxwell explains why Annex 21 is not just a regulatory hurdle, but a key commercial risk point.

In today’s Pharma Pulse, Walgreens reshapes pharmacist roles, pharmacies expand injectable access, GoodRx and Eli Lilly broaden GLP-1 access, radiopharma investment grows, and AbbVie signs a $745 million Haisco licensing deal.

Lilly's Foundayo and Zepbound KwikPen are now available on GoodRx for self-pay access.

In this week’s Pharma Pulse, tariffs reshape drug supply, a fragile ceasefire tests global pharma, Wegovy goes higher-dose, and patients still can't get appointments fast enough.

Manasi Salgaonkar examines how accurate class of trade research enables precise pricing, contract eligibility, and compliance.

Anthony Bianciella explains how rare disease brands lose patients because journey maps prioritize prescribing intent over the complex, unfamiliar logistics of post-diagnosis access.

Eli Lilly’s newest GLP-1, Foundayo (orforglipron), is the first FDA-approved weight loss pill that can be taken without food or water restrictions.

Amber Hussain-Siddique says operational discipline in inventory and logistics is the vital, yet overlooked, key to sustaining low-cost generic drug supplies in the U.S.

To fix America's drug shortages, pharma must look beyond manufacturing and overhaul how medicines are allocated and delivered to smaller hospitals.

In today's Pharma Pulse, the FDA flags misleading promotional claims from ImmunityBio regarding its cancer therapy and MedImpact launches new solutions to address the skyrocketing employer costs of GLP-1 weight management therapies.

New Benefit 360 and Direct Fund models aim to bridge the gap between clinical eligibility and employer-sponsored coverage.

Workflow alignment, e-prescribing integration, and behavior change strategies are critical to reducing friction across the direct-to-patient ecosystem.

In today's Pharma Pulse, the FDA grants expanded approval for Imcivree, while new research highlights how optimizing pharmacy technician roles can significantly boost vaccine access and uptake.